Market Overview

UPDATE: Jefferies Upgrades Pfizer from Hold to Buy, Boosts Target to $38

Share:
Related PFE
Incyte PDUFA Date Pushed Back, JMP Discusses Impact
All The Markets Trump Moved During His Speech Today
The Vetr community has upgraded $PFE to 4.5-Stars. (Vetr)

Pfizer (NYSE: PFE) has received an upgraded rating from Hold to Buy and a raised price target from $33 to $38 at Jefferies Tuesday morning.

Pfizer's upgrades follows acknowledgments that Oncology and restructuring are key themes for the Pharma sector and Pfizer has both of those covered with palbociclib looking like it could launch before year end, according to the firm's Jeffery Holland.

The Jefferies analyst expects the market to soon be reflecting incremental value in the shares based on the drivers above, adding significant upside to the companies shares.

Shares of Pfizer are up 2.7 percent to $31.42 at last check following the upgrade.

Latest Ratings for PFE

DateFirmActionFromTo
Dec 2016GuggenheimInitiates Coverage OnNeutral
Nov 2016BarclaysUpgradesEqual-WeightOverweight
Nov 2016BMO CapitalDowngradesOutperformMarket Perform

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Analyst Color News Upgrades Price Target Analyst Ratings

 

Related Articles (PFE)

View Comments and Join the Discussion!